Role of glutathione in cancer pathophysiology and therapeutic interventions

Journal of Experimental Therapeutics and Oncology

Volumn 9, Issue 4, 2012, Pages 303-316

  Singh, Simendra ^a   Khan, Amir R ^a   Gupta, Alok K ^b,c  

^a SHARDA UNIVERSITY   (India)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Apoptosis; BSO; Cancer; GSH; Resistance

Indexed keywords

'TAXOL'; 4 HYDROXYPHOSPHAMIDE; ACROLEIN; ALDOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BUTHIONINE SULFOXIMINE; CANFOSFAMIDE; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; EZATIOSTAT; GEMCITABINE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; IFOSFAMIDE; IMEXON; MELPHALAN; METHOTREXATE; MITOXANTRONE; NITROSOUREA; PACLITAXEL; THIOTEPA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

ADVANCED CANCER; APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG DETOXIFICATION; DRUG POTENTIATION; GLUTATHIONE METABOLISM; GLUTATHIONYLATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MELANOMA; NONHUMAN; OVARY CANCER; OXIDATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENT CANCER; REVIEW; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; GLUTATHIONE; HUMANS; METABOLIC DETOXICATION, DRUG; NEOPLASMS;

EID: 84860620140     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Townsend DM, Tew KD, Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother 57: 145-155, 2003. (Pubitemid 36740460)
2. Valencia E, Marin A, Hardy G. Glutathione-nutritional and pharmacological viewpoints: Part II. Nutrition 17: 485-486, 2001.
3. Green RM, Graham M, O'Donovan M R, Chipman JK, Hodges NJ. Subcellular compartmentalization of glutathione: correlations with parameters of oxidative stress related to genotoxicity. Mutagenesis 21: 383-390, 2006. (Pubitemid 44691127)
4. Sies H. Glutathione and its role in cellular functions. Free Rad Biol Med 27: 916-921, 1999. (Pubitemid 29507465)
5. Franco R, Schoneveld OJ, Pappa A, Panayiotidis MI. The central role of glutathione in the pathophysiology of human diseases. Arch Physiol Biochem 113: 234-258, 2007.
6. Anderson ME. Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact 111-112: 1-14, 1998. (Pubitemid 28271929)
7. Masella R, Di Benedetto R, Vari R, Filesi C, Giovannini C. Novel mechanisms of natural antioxidant compounds in biological systems: Involvement of glutathione and glutathione related enzymes. J Nutr Biochem 16: 577-586, 2005. (Pubitemid 41338369)
8. Tandogǎ;n B, Ulusu NN. Kinetic mechanism and molecular properties of glutathione reductase. FABAD J Pharm Sci 31: 230-237, 2006.
9. Hiranruengchok R, Harris C. Formation of protein-glutathione mixed disulfides in the developing rat conceptus following diamide treatment in vitro. Teratology 52: 196-204, 1995. (Pubitemid 26027208)
10. Paolicchi A, Dominici S, Pieri L, Maellaro E, Pompella A. Glutathione catabolism as a signaling mechanism. Biochem Pharmacol 64: 1027-1035, 2002. (Pubitemid 35232278)
11. Estrela JM, Ortega A, Obrador E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43: 143-181, 2006. (Pubitemid 43860449)
12. Gukasyan HJ, Lee VH, Simityan H, Kim KJ, Kannan R. Thermodynamic stoichiometry of Na+-coupled glutathione transport. Can J Physiol Pharmacol 84: 1223-1227, 2006. (Pubitemid 46465935)
13. Hammond CL, Lee TK, Ballatori N. Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes. J Hepatol 34: 946-954, 2001. (Pubitemid 32595199)
14. Ballatori N, Hammond CL, Cunningham JB, Krance SM, Marchan R. Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol Appl Pharmacol 204: 238-255, 2005. (Pubitemid 40545229)
15. Yeh CC, Hou MF, Wu SH, Tsai SM, Lin SK, Hou LA, Ma H, Tsai LY. A study of glutathione status in the blood and tissues of patients with breast cancer. Cell Biochem Funct 24: 555-559, 2006.
16. Suess E, Malessa S, Ungersböck K, Kitz P, Podreka I, Heimberger K, Hornykiewicz O, Deecke L. Technetium-99md, 1-hexamethylpropyleneamine oxime (HMPAO) uptake and glutathione content in brain tumors. J Nucl Med 32: 1675-1681, 1991.
17. Grubben MJ, van den Braak CC, Nagengast FM, Peters WH. Low colonic glutathione detoxification capacity in patients at risk for colon cancer. Eur J Clin Invest 36: 188-192, 2006. (Pubitemid 43341270)
18. Peters WH, van Schaik A, Peters JH, van Goor H. Oxidisedand total non-protein bound glutathione and related thiols in gallbladder bile of patients with various gastrointestinal disorders. BMC Gastroenterol 7: 7, 2007.
19. Gupta A, Srivastava S, Prasad R, Natu SM, Mittal B, Negi MP, Srivastava AN. Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response. Respirology 15: 349-356, 2010.
20. Almadori G, Bussu F, Galli J, Limongelli A, Persichilli S, Zappacosta B, Minucci A, Paludetti G, Giardina B. Salivary glutathione and uric acid levels in patients with head and neck squamous cell carcinoma. Head Neck 29: 648-654, 2007. (Pubitemid 47168235)
21. Kearns PR, Pieters R, Rottier MM, Pearson AD, Hall AG. Raised blast glutathione levels are associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 97: 393-398, 2001. (Pubitemid 32060323)
22. Kawai H, Kiura K, Tabata M, Yoshino T, Takata I, Hiraki A, Chikamori K, Ueoka H, Tanimoto M, Harada M. Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy 305-314, 2002.
23. Bracht K, Boubakari, Grünert R, Bednarski PJ. Correlations between the activities of 19 anti-tumor agents and the intracellular glutathione concentrations in a panel of 14 human cancer cell lines: comparisons with the National Cancer Institute data. Anticancer Drugs 17: 41-51, 2006.
24. Britten RA, Green JA, Warenius HM. Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Radiat Oncol Biol Phys 24: 527-531, 1992.
25. Kuppusamy P, Li H, Ilangovan G, Cardounel AJ, Zweier JL, Yamada K, Krishna MC, Mitchell JB. Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res 62: 307-312, 2002. (Pubitemid 34074020)
26. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22: 7369-7375, 2003.
27. Dourado DF, Fernandes PA, Mannervik B, Ramos MJ. Glutathione transferase: new model for glutathione activation. Chemistry 14: 9591-9598, 2008.
28. Armstrong RN. Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem Res Toxicol 10: 2-18, 1997. (Pubitemid 27044902)
29. Blair IA. Analysis of endogenous glutathione-adducts and their metabolites. Biomed Chromatogr 24: 29-38, 2010.
30. Lo HW, Ali-Osman F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol 7: 367-374, 2007. (Pubitemid 47289267)
31. Yang P, Ebbert JO, Sun Z, Weinshilboum RM. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 24: 1761-1769, 2006. (Pubitemid 46622148)
32. Dalle-Donne I, Rossi R, Colombo G, Giustarini D, Milzani A. Protein S-glutathionylation: a regulatory device from bacteria to humans. Trends Biochem Sci 34: 85-96, 2009.
33. Dalle-Donne I, Rossi R, Giustarini D, Colombo R, Milzani A. S-glutathionylation in protein redox regulation. Free Rad Biol Med 43: 883-898, 2007. (Pubitemid 47223636)
34. Mieyal JJ, Gallogly MM, Qanungo S, Sabens EA, Shelton MD. Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid Redox Signal 10: 1941-1988, 2008.
35. Giles GI. The redox regulation of thiol dependent signaling pathways in cancer (2006). Curr Pharm Des; 12: 4427-43. (Pubitemid 44835155)
36. England K, Cotter TG. Direct oxidative modifications of signalling proteins in mammalian cells and their effects on apoptosis. Redox Rep 10: 237-245, 2005. (Pubitemid 44111130)
37. Biswas S, Chida AS, Rahman I. Redox modifications of proteinthiols: emerging roles in cell signaling. Biochem Pharmacol 71: 551-564, 2006. (Pubitemid 43121989)
38. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 6: 521-534, 2006. (Pubitemid 43980541)
39. Markovic J, Borrás C, Ortega A, Sastre J, Viña J, Pallardó, FV. Glutathione is recruited into the nucleus in early phases of cell proliferation. J Biol Chem 282: 20416-20424, 2007. (Pubitemid 47099986)
40. Green RM, Graham M, O'Donovan MR, Chipman JK, Hodges NJ. Subcellular compartmentalization of glutathione: correlations with parameters of oxidative stress related to genotoxicity. Mutagenesis 21: 383-390, 2006. (Pubitemid 44691127)
41. Rahman I. Regulation of nuclear factor-κB, activator protein-1, and glutathione levels by tumor necrosis factor-α and dexamethasone in alveolar epithelial cells. Biochem Pharmacol 60: 1041-1049, 2000.
42. Bellomo G, Palladini, G, Vairetti M. Intranuclear distribution, function and fate of glutathione and glutathione-S-conjugate in living rat hepatocytes studied by fluorescence microscopy. Microsc Res Tech 36: 243-252, 1997. (Pubitemid 27188146)
43. Pallardó, FV, Markovic J, García JL, Viña J. Role of nuclear glutathione as a key regulator of cell proliferation. Mol Aspects Med 30: 77-85, 2009.
44. Pellny TK, Locato V, Vivancos PD, Markovic J, De Gara L, Pallardó FV, Foyer CH. Pyridine nucleotide cycling and control of intracellular redox state in relation to poly(ADP-ribose) polymerase activity and nuclear localisation of glutathione during exponential growth of Arabidopsis cells in culture. Mol Plant 2: 442-456, 2009.
45. Morales A, Miranda M, Sánchez-Reyes A, Biete A, Fernández-Checa JC. Oxidative damage of mitochondrial and nuclear DNA induced by ionizing radiation in human hepatoblastoma cells. Int J Radiat Oncol Biol Phys 42: 191-203, 1998. (Pubitemid 28435613)
46. Lash LH. Mitochondrial glutathione transport: Physiological, pathological and toxicological implications. Chem-Biol Interact 163: 54-67, 2006. (Pubitemid 44572210)
47. Savaskan NE, Ufer C, Kühn H, Borchert A. Molecular biology of glutathione peroxidase 4: from genomic structure to development expression and neural function. J Biol Chem 388: 1007-1017, 2007. (Pubitemid 47584303)
48. Nomura K, Imai H, Koumura T, Arai M, Nakagawa Y. Mitochondrial phospholipid hydroperoxide glutathione peroxidase suppresses apoptosis mediated by a mitochondrial death pathway. J Biol Chem 274: 29294-29302, 1999.
49. Pechtelidou A, Beis I, Gaitanaki C. Transient and sustained oxidative stress differentially activate the JNK1/2 pathway and apoptotic phenotype in H9c2 cells. Mol Cell Biochem 309: 177-189, 2008.
50. Sandau K, Pfeilschifter J, Brüne B. Nitric oxide and superoxide induced p53 and Bax accumulation during mesangial cell apoptosis. Kidney Int 52: 378-386, 1997. (Pubitemid 27359580)
51. Lee HB, Yu MR, Song JS, Ha H. Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by human peritoneal mesothelial cells. Kidney Int 65: 1170-1179, 2004. (Pubitemid 38406955)
52. Fratelli M, Goodwin LO, Ørom UA, Lombardi S, Tonelli R, Mengozzi M, Ghezzi P. Gene expression profiling reveals a signaling role of glutathione in redox regulation. Proc Natl Acad Sci USA 102: 13998-14003, 2005. (Pubitemid 41377692)
53. Limón-Pacheco JH, Hernández NA, Fanjul-Moles ML, Gonsebatt ME. Glutathione depletion activates mitogenactivated protein kinase (MAPK) pathways that display organspecific responses and brain protection in mice. Free Rad Biol Med 43: 1335-1347, 2007. (Pubitemid 47432899)
54. Ramos AM, Fernandez C, Amrán D, Esteban D, de Blas E, Palacios MA, Aller P. Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis. J Cell Physiol 209: 1006-1015, 2006. (Pubitemid 44665723)
55. Ortiz C, Caja L, Sancho P, Bertran E, Fabregat I. Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of doxorubicin in rat hepatoma cells: role of reactive oxygen species production and glutathione depletion. Biochem Pharmacol 75: 1935-1945, 2008.
56. Ramos AM, Fernández C, Amrán D, Sancho P, de Blas E, Aller P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 105: 4013-4020, 2005. (Pubitemid 40656150)
57. Kern JC, Kehrer JP. Free radicals and apoptosis: relationships with glutathione, thioredoxin, and the BCL family of proteins. Front Biosci 10: 1727-1738, 2005. (Pubitemid 40532954)
58. Franco R, Cidlowski JA. SLCO/OATP-like transport of glutathione in FasL-induced apoptosis: glutathione efflux is coupled to an organic anion exchange and is necessary for the progression of the execution phase of apoptosis. J Biol Chem 281: 29542-29557, 2006. (Pubitemid 44536962)
59. Hammond CL, Marchan R, Krance SM, Ballatori N. Glutathione export during apoptosis requires functional multidrug resistance-associated proteins. J Biol Chem 282: 14337-14347, 2007. (Pubitemid 47100459)
60. Friesen C, Kiess Y, Debatin KM. A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death Differ 11 Suppl 1: S73-85, 2004. (Pubitemid 39136800)
61. Cazanave S, Berson A, Haouzi D, Vadrot N, Fau D, Grodet A, Lettéron P, Feldmann G, El-Benna J, Fromenty B, Robin MA, Péssayre D. High hepatic glutathione stores alleviate Fas-induced apoptosis in mice. J Hepatol 46: 858-868, 2007. (Pubitemid 46546601)
62. Armstrong JS, Jones DP. Glutathione depletion enforces the mitochondrial permeability transition and causes cell death in Bcl-2 overexpressing HL60 cells. FASEB J 16: 1263-1265, 2002.
63. Valverde M, Rojas E, Kala SV, Kala G, Lieberman MW. Survival and cell death in cells constitutively unable to synthesize glutathione. Mutat Res 594: 172-180, 2006. (Pubitemid 43170997)
64. Sato T, Machida T, Takahashi S, Iyama S, Sato Y, Kuribayashi K, Takada K, Oku T, Kawano Y, Okamoto T, Takimoto R, Matsunaga T, Takayama T, Takahashi M, Kato J, Niitsu Y. Fas-mediated apoptosome formation is dependent on reactive oxygen species derived from mitochondrial permeability transition in Jurkat cells. J Immunol 173: 285-296, 2004. (Pubitemid 38797353)
65. D'Alessio M, De Nicola M, Coppola S, Gualandi G, Pugliese L, Cerella C, Cristofanon S, Civitareale P, Ciriolo MR, Bergamaschi A, Magrini A, Ghibelli L. Oxidative Bax dimerization promotes its translocation to mitochondria independently of apoptosis. FASEB J 19: 1504-1506, 2005. (Pubitemid 41279012)
66. Coppola S, Ghibelli L. GSH extrusion and and the mitochondrial pathway of apoptotic signalling. Biochem Soc Trans 28: 56-61, 2000. (Pubitemid 30103213)
67. Hancock JT, Desikan R, Neill SJ. Cytochrome c, glutathione, and the possible role of redox potentials in apoptosis. Ann N Y Acad Sci 1010: 446-448, 2003. (Pubitemid 38265023)
68. Meurette O, Lefeuvre-Orfila L, Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel MT. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor-α related apoptosis-inducing ligand/anticancer drug combinations. Clin Cancer Res 11: 3075-3083, 2005. (Pubitemid 40525214)
69. Hentze H, Schmitz I, Latta M, Krueger A, Krammer PH, Wendel A. Glutathione dependence of caspase-8 activation at the death-inducing signaling complex. J Biol Chem 277: 5588-5595, 2002. (Pubitemid 34968612)
70. Zimmermann AK, Loucks FA, Schroeder EK, Bouchard RJ, Tyler KL, Linseman DA. Glutathione binding to the Bcl-2 homology-3 domain groove: a molecular basis for Bcl-2 antioxidant function at mitochondria. J Biol Chem 282: 29296-29304, 2007. (Pubitemid 350043369)
71. Voehringer DW, McConkey DJ, McDonnell TJ, Brisbay S, Meyn RE. Bcl-2 expression causes redistribution of glutathione to the nucleus. Proc Natl Acad Sci USA 95: 2956-2960, 1998. (Pubitemid 28135836)
72. Voehringer DW. Bcl-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. Free Rad Biol Med 27: 945-950, 1999. (Pubitemid 29507468)
73. Jang J-H, Surh Y-J. Potentiation of cellular antioxidant capacity of Bcl-2: implications for its antiapoptotic function. Biochem Pharmacol 66: 1371-1379, 2003. (Pubitemid 38373323)
74. Benlloch M, Ortega A, Ferrer P, Segarra R, Obrador E, Asensi M, Carretero J, Estrela JM. Acceleration of glutathione efflux and inhibition of gamma-glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. J Biol Chem 280: 6950-6959, 2005. (Pubitemid 40341251)
75. Richardson RJ, Murphy SD. Effect of glutathione depletion on tissue deposition of methylmercury in rats. Toxicol App Pharmacol 31: 505-519, 1975.
76. Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol 60: 749-758, 2000. (Pubitemid 30621659)
77. Moulder S, Dhillon, Ng C, Hong D, Wheler J, Naing A, Tse S, LePagtia A, Dorr RT, Hersh EM, Boytim ML, Kurzrock R. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs 28: 634-640, 2010.
78. Cohen SJ, Zalupski MM, Modiano MR, Conkling P, Patt YZ, Davis P, Dorr RT, Boytim ML, Hersh EM. A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cancer Chemother Pharmacol 66: 287-294, 2009.
79. Cohen SJ, Zalupski MM, Conkling P. A phase II randomized double blind multicenter trial of gemcitabine (Gem) plus imexon (IMX) versus Gem plus placebo (P) in patients with chemotherapy-naïve pancreatic adenocarcinoma (PC). J Clin Oncol 28 (15s): abstract 4076, 2010.
80. Iida T, Kijima H, Urata Y, Goto S, ihara Y, Oka M, Kohno S, Scanlon KJ, Kondo T. Hammerhead ribozyme against gammaglutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther 8: 803-814, 2001. (Pubitemid 32983137)
81. Yao KS, Godwin AK, Johnson SW, Ozols RF, O'Dwyer PJ, Hamilton TC. Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatinsensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 55: 4367-4374, 1995.
82. Griffith OW. Mechanism of Action, Metabolism, and Toxicity of Buthionine Sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 257: 13704-13712, 1982. (Pubitemid 13187133)
83. Russo A, DeGraff W, Friedman N, Mitchell JB. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res 46: 2845-2848, 1986. (Pubitemid 16074292)
84. Wondrak GT. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 11: 3013-3069, 2009.
85. Anderson CP, Reynolds CP. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant 30: 135-140, 2002. (Pubitemid 34993851)
86. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 12: 194-205, 1994. (Pubitemid 24020640)
87. Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G. Phase I study of continuous-infusion L-S,Rbuthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 89: 1789-1796, 1997. (Pubitemid 27516233)
88. New Approaches to Neuroblastoma Therapy Consortium. Melphalan and buthionine sulfoximine followed by bone marrow or peripheral stem cell transplantation in treating children with resistant or recurrent neuroblastoma. [ClinicalTrials.gov identifier: NCT00005835]. US National Institutes of Health (USA). Available from URL: http://www.clinicaltrials.gov.
89. Duke University. Buthionine sulfoximine and an isolated limb infusion of melphalan in treating patients with persis- tent or recurrent stage III malignant melanoma [ClinicalTrials. gov identifier: NCT00661336]. US National Institutes of Health (USA). Available from URL: http://www.clinicaltrials.gov.
90. A Phase II Trial of IV-L-PAM and BSO in Patients with Relapsed or Refractory Ovarian Cancer (McGill Center for Translational Research in Cancer: Quebec, Canada).
91. Hamilton D, Batist G. TLK-199 (Telik). IDrugs 8: 662-669, 2005.
92. O'Brien ML, Vulevic B, Freer S, Boyd J, Shen H, Tew KD. Glutathione peptidomimetic drug modulator of multidrug resistance-associated protein. J Pharmacol Exp Ther 291: 1348-1355, 1999.
93. Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H 3rd, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GL. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol 2: 20, 2009.
94. Tew KD. TLK-286: a novel glutathione S-transferase-activated prodrug. Expert Opin Invest Drugs 14: 1047-1054, 2005. (Pubitemid 41131655)
95. Verschraegen CF, Smith HO, Lee FC, Cathcart C, Norenberg JP. TLK-286. IDrugs 7: 771-781, 2004.
96. Morgan AS, Sanderson PE, Borch RF, Tew KD, Niitsu Y, Takayama T, Von Hoff DD, Izbicka E, Mangold G, Paul C, Broberg U, Mannervik B, Henner WD, Kauvar LM. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Res 58: 2568-2575, 1998. (Pubitemid 28275427)
97. Rosen LS, Laxa B, Boulos L, Wiggins L, Keck JG, Jameson AJ, Parra R, Patel K, Brown GL. Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies. Clin Cancer Res 10: 3689-3698, 2004. (Pubitemid 38697602)
98. Kavanagh JJ, Gershenson DM, Choi H, Lewis L, Patel K, Brown GL, Garcia A, Spriggs DR. Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer 15: 593-600, 2005. (Pubitemid 41022895)
99. Townsend DM, Pazoles CJ, Tew KD. NOV-002, a mimetic of glutathione disulfide. Expert Opin Invest Drugs 17: 1075-1083, 2008.
100. Gumireddy K, Pazoles C, Vulfson E, et al. Inhibition of tumor cell invasion and ErbB2/PI3K signalling pathways by the glutathione disulfide-mimetic NOV-002 [abstract 1807]. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver (CO) USA.
101. Townsend DM, Bowers R, Pazoles CJ, et al. NOV-002 suppresses tumor cell growth by modulating redox-sensitive cell signaling (2009). Mol Cancer Ther 8 (12 Suppl. 1): Abstract C301.
102. Pazoles CJ, Gerstein H. NOV-002, a chemoprotectant/immunomodulator, added to first-line carboplatin/paclitaxel in advanced non-small cell lung cancer (NSCLC): a randomized phase 1/2, open-label, controlled study [abstract 17021]. J Clin Oncol 24 18S Pt 1 (Jun 20 Suppl.): 668s, 2006.
103. Montero AJ, Diaz-Montero CM, Slingerland J, et al. Phase 2 study of neoadjuvant treatment with cellular redox modulator NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel (AC T) in patients with stage II-III HER-2(-) breast cancer [abstract P1-11-05]. 33rd Annual Breast Cancer Symposium; 2010 Dec 8-12; San Antonio (TX) USA.
104. Krasner CN, Seiden MV, Penson RT et al. NOV-002 plus carboplatin in platinum-resistant ovarian cancer [abstract no. 5593]. J Clin Oncol 26 (May 20 Suppl.): 315s, 2008.
105. Cvek B. Targeting malignancies with disulfiram (antabuse): multidrug resistance, angiogenesis, and proteasome. Curr Cancer Drug Targets 11: 332-337, 2011.
106. Cen D, Brayton D, Shahandeh B, Meyskens FL Jr, Farmer PJ. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem 47: 6914-6920, 2004. (Pubitemid 40053779)
107. University of California. Disulfiram in metastatic melanoma [ClinicalTrials.gov identifier: NCT00256230]. US National Institutes of Health (USA). Available from URL: http://www.clinicaltrials.gov.
108. Hadassah Medical Organization. Initial assessment of the effect of the addition of disulfiram (Antabuse) to standard chemotherapy in lung cancer [ClinicalTrials. gov identifier: NCT00312819]. US National Institutes of Health (USA). Available from URL: http://www.clinicaltrials.gov.
109. University of Utah. Phase I study of disulfiram and copper gluconate for the treatment of refractory solid tumors involving the liver [ClinicalTrials.gov identifier: NCT00742911]. US National Institutes of Health (USA). Available from URL: http://www.clinicaltrials.gov.
110. Ji B, Ito K, Sekine S, Tajima A, Horie T. Ethacrynic-acid-induced glutathione depletion and oxidative stress in normal and Mrp2-deficient rat liver. Free Rad Biol Med 37: 1718-1729, 2004. (Pubitemid 39441056)
111. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13: 1859-1876, 2006.
112. Barbson JR, Reed DJ. Inactivation of glutathione reductase by 2-chloroethyl nitrosourea-derivatised isocyanates. Biochem Biophys Res Comm 83: 745-762, 1978.